UNSPSC 51312104: Lodoxamide

This classification denotes a mast cell stabilizer with the molecular formula C11H6ClN3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SPU695OD73, chemically known as n,n-(2-chlor-5-cyan-3-phenylen)dioxamsaeure but generally known as lodoxamide, which bears US NIH Compound Identifier 44564. European Medicines Agency schedules Lodoxamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08553MIG.

UNSPSC 51312104 Lodoxamide, a Commodity code, nominally names a specific ophthalmologic antihistamine; however, recent state and local solicitation activity under this code shows minimal alignment with that product category. The single identified recent opportunity—Seminole County, Florida's IFB60459723LAS—solicits naloxone (an opioid antagonist) and safe drug deactivation systems for community health support, neither of which matches the lodoxamide specification. State and local procurement offices appear to apply this code inconsistently or as a catch-all for pharmaceutical and health-supply acquisitions outside their primary taxonomic scope.

Seminole County Community Health Building, the identified issuing body in the recent-opportunities record, posted an IFB on June 30, 2026 (due July 26, 2023, per the notice date) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county health facility in Sanford, Florida. Vendors must include all shipping and delivery costs in their bids, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation and liability insurance. The contract terms include an initial two-year period with a one-year renewal option and a three-month probationary termination window. The notice indicates potential FEMA funding and associated federal compliance obligations. The code shows limited recent activity; this single opportunity does not establish a pattern of state and local government demand under the lodoxamide classification.